Nodality, Inc. Announces Expansion of Company's Patent Estate Covering Programs to Improve the Treatment of Patients With Severe Diseases in Immunology, Oncology, and Autoimmune Diseases
4/10/2013 12:13:38 PM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., a next-generation life sciences company partnering with leading firms to advance precision medicine, announced today the issuance by the United States Patent and Trademark Office (USPTO) of Patent Number 8,394,599, which broadly covers methods for applying the Company’s Single Cell Network Profiling (SCNP) technology. SCNP provides the core foundation for Nodality’s programs dedicated to making medicines better by increasing the productivity of therapeutic R&D programs, enhancing life cycle management for commercialized drugs, and introducing new predictive diagnostics. With the issuance of this patent, Nodality now owns or has exclusive rights to more than 25 issued patents and 80 patent applications.
comments powered by